E
Embera NeuroTherapeutics
Embera NeuroTherapeutics, Inc.
About Embera NeuroTherapeutics
Embera NeuroTherapeutics, Inc. is a clinical-stage specialty pharmaceutical company founded in 2007, operating with a focus on developing novel treatments for a range of addiction disorders. The company’s foundation stems from over 30 years of NIH-funded research by its scientific founder, Professor Nicholas Goeders, Ph.D., at Louisiana State University. Professor Goeders' work on the stress hypothesis of addiction led to the key insight that a combination of two existing drugs could more effectively modulate the body's stress response system, which is a primary driver of cravings and relapse in addiction.
The company's lead product candidate, EMB-001, is a patented combination of two FDA-approved medications: metyrapone, a cortisol synthesis inhibitor, and oxazepam, a benzodiazepine. This formulation is designed to simultaneously target multiple stress-related neurological pathways to reduce cravings and help patients maintain abstinence from substances like cocaine and nicotine. By combining these two drugs at lower doses, Embera aims to maximize efficacy while minimizing potential side effects compared to using either drug alone. The business model is centered on advancing EMB-001 through clinical trials to gain regulatory approval, funded by a combination of private equity and significant non-dilutive grant funding from institutions like the National Institute on Drug Abuse (NIDA). To date, the company has raised over $24 million and has progressed EMB-001 into Phase 2 clinical studies for both smoking cessation and cocaine use disorder.
Under the leadership of executives like former CEO Bob Linke, who brought extensive experience from both large pharmaceutical companies and private equity-backed startups, Embera has established its strategic direction and assembled a veteran product development team. The company's strategy includes leveraging its development engine to form partnerships that can optimize late-stage clinical development and maximize the global commercial potential of its treatments. Having completed a Phase 1 safety study, the company initiated Phase 2a trials for smoking cessation and cocaine use disorder, with positive topline data indicating that EMB-001 is well-tolerated. These milestones position Embera to address significant unmet needs in the multi-billion dollar addiction treatment market, particularly for conditions like cocaine use disorder, for which no FDA-approved medication currently exists.
Source: Dealroom company dataNews
Open roles
Embera NeuroTherapeutics in the Sudbury ecosystem
The Embera NeuroTherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institute on Drug Abuse (NIDA)
Series A5 investors entered at this stage
HRA Pharma- BCBVM Capital
Keiretsu Capital
Keiretsu Forum Northwest
Innovation Catalyst
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Embera NeuroTherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Embera NeuroTherapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
